With an EU regulatory approval looking imminent for Pixuvri (pixantrone) and Phase III trials ongoing for that drug as well as tosedostat, CTI BioPharma Corp. might appear to have more than enough activity at the moment. But on April 19, it paid $30 million upfront to SBIO Pte. Ltd. for global rights to JAK2 inhibitor pacritinib, giving the Seattle-based biotech three Phase III candidates in blood cancer.
CTI Sees Ideal Pipeline Acquisition In JAK2 Inhibitor Abandoned By Onyx
Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.
More from United States
• By
Former Acting FDA Commissioner Sara Brenner is said to have asked Tracy Beth Høeg, new special assistant to the commissioner, to help reexamine the application. Høeg’s position at the agency is raising concerns about the FDA's ongoing approach to vaccine regulation.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
As CMS administrator, Mehmet Oz will oversee the second year of Medicare drug price negotiations and Part D redesign issues, but will have experienced deputies to help.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.
More from North America
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
• By
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.